Vivani Medical is a pre-clinical-stage developer of long-term pharmaceutical implants aimed at revolutionizing the treatment of patients with chronic diseases. Leveraging its proprietary NanoPortal™ platform, Vivani’s portfolio of tiny, sub-dermal drug implants address medication non-adherence by providing steady levels of medication over a target duration of six months or longer. Vivani is developing two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide). In addition, the company is developing NPM-119, a lower dose exenatide implant for the treatment of type 2 diabetes.